Form 4: Oscar Health CEO Sells Shares for Tax Withholding

Oscar Health CEO Mark Bertolini sold a significant number of Class A common stock shares to cover tax obligations related to vested performance stock units, executing a pre-planned Rule 10b5-1 transaction.

Summary

• Mark Bertolini, CEO of Oscar Health, Inc., reported the sale of Class A Common Stock on June 29 and June 30, 2026.
• These sales were conducted to satisfy tax withholding obligations stemming from the vesting of performance stock units on April 3, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan, initially entered into on November 10, 2025, and amended on March 24, 2026.
• A total of 1,183,970 shares were sold across multiple transactions at weighted average prices ranging from $28.35 to $30.08.
• Following these transactions, Bertolini beneficially owns 7,751,570 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant share sales by a CEO can be a negative signal, the clear explanation of tax withholding and the use of a Rule 10b5-1 plan mitigate potential concerns.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a structured and planned approach to managing equity compensation.
• The sales were specifically to cover tax withholding obligations, a common and expected event for executives upon vesting of equity awards.

Negatives

• A significant number of shares (1,183,970) were sold by the CEO, which could be perceived negatively by the market, despite the stated reason.
• The sales occurred at prices ranging from $28.35 to $30.08, reflecting the prevailing market prices at the time of the transactions.

Risks

• Potential for negative market perception of significant insider selling, even if for tax purposes.
• The Rule 10b5-1 plan itself, while designed for defense, can sometimes be scrutinized if not properly structured or if trades appear opportunistic.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on November 10, 2025 and amended and restated on March 24, 2026.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Industry Context

StockSavvy.ai notes that insider selling, particularly by CEOs, is a common event, especially when tied to tax obligations from equity compensation. The use of a Rule 10b5-1 plan is a standard practice to mitigate concerns about insider trading, demonstrating adherence to regulatory guidelines.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, although the explanation of tax withholding and the Rule 10b5-1 plan should provide some reassurance.
• Employees: The transaction is a standard part of executive compensation and does not directly impact most employees.
• Management: Bertolini's remaining beneficial ownership indicates continued significant stake in the company.

Next Steps

• The reporting person will continue to hold the remaining beneficially owned shares.
• The company may see continued equity award vesting and subsequent tax-related sales by executives in the future.

Key Dates

Recommendation

The filing reports routine transactions by the CEO to cover tax obligations related to vested equity, executed under a pre-planned Rule 10b5-1 trading plan. While significant selling can be a concern, the context provided suggests it is not indicative of a change in the CEO's fundamental view of the company's prospects. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Oscar Health's business performance.

Keywords

Oscar Health, OSCR, Form 4, Insider Trading, Stock Sale, CEO, Mark Bertolini, Rule 10b5-1, Tax Withholding, Performance Stock Units, Equity Compensation